CJC-1295 and Ipamorelin: dosing in the published literature

CJC-1295: what the human trials used

The principal human dataset is Teichman et al. (2006), published in the Journal of Clinical Endocrinology & Metabolism. It comprised two randomised, placebo-controlled, double-blind ascending-dose trials of 28 and 49 days in healthy adults aged 21 to 61, given CJC-1295 in ascending single doses or in multiple weekly or biweekly doses.

After a single subcutaneous injection the study reported dose-dependent increases in mean plasma GH of two- to ten-fold lasting six days or more, and increases in mean plasma IGF-I of 1.5- to three-fold lasting nine to eleven days. The estimated half-life of CJC-1295 was 5.8 to 8.1 days. The authors concluded the compound was safe and relatively well tolerated, particularly at doses of 30 or 60 µg/kg.

Two things follow. The dose is expressed per kilogram of bodyweight, so a single figure in milligrams is not what the trial tested. And the multi-day half-life is why the published schedules are weekly or biweekly rather than daily — the exposure from one injection is still present a week later.

Ipamorelin: no published human dose-ranging trial

Ipamorelin was characterised by Raun et al. (1998) in the European Journal of Endocrinology, the paper that named it the first selective growth hormone secretagogue. It is a pentapeptide identified within a series derived from growth hormone-releasing peptide-1, and the selectivity claim is that it releases GH with less effect on other pituitary hormones than the earlier GHRP compounds.

That work is preclinical. There is no published human dose-ranging trial for ipamorelin comparable to the CJC-1295 dataset, so no human dose has been established for it. Any ipamorelin dosing figure circulating online is not traceable to a human trial.

The combination has not been studied in humans

CJC-1295 and ipamorelin are almost always discussed together, and the rationale is mechanistic: a GHRH analogue raises the size of a growth hormone pulse while a secretagogue acting on the ghrelin receptor triggers one. The reasoning is sound as pharmacology. It is not the same thing as evidence.

No published human trial has administered the two compounds together and measured the result. Dose figures presented for the combination are therefore derived from the individual compounds at best, and invented at worst.

What Body Pharm states about its own pen

Separate from the literature, Body Pharm supplies CJC-1295 and ipamorelin in one pre-loaded 20 mg 3 mL pen and describes its own protocol on the product page and as the bedtime protocol on the sleep page: one dose before bed, five nights per week, on an empty stomach. That is the supplier’s stated protocol for its own product, not a finding from any of the studies above, and it is presented as such.

Every batch is third-party tested for identity, purity and sterility, and the certificate of analysis for the specific lot is reachable from the QR code on the pen.